People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology, Manufacturing / Industrial
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Codexis, Inc. | — | Biotechnology | Series C | $50.0M | $2.0B | 2019 |
| Scientific Industries Inc | — | Manufacturing / Industrial | Series A | $34.7M | $5.2M | 2025 |
John Nicols at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Nicols on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Smith | 1 | 42 |
| John Moore | 1 | 12 |
| Thomas Baruch | 1 | 4 |
| Patrick Yang | 1 | 3 |
| Dennis Wolf | 1 | 3 |
| Kathleen Glaub | 1 | 3 |
| Christopher Cox | 1 | 2 |
| Marcus Frampton | 1 | 2 |
| John Watkins | 1 | 1 |
| Gordon Sangster | 1 | 1 |
| Pam Cheng | 1 | 1 |
| Bernard Kelley | 1 | 1 |
| Byron Dorgan | 1 | 1 |
| Helena Santos | 1 | 1 |
| Michael Blechman | 1 | 1 |
| Juergen Schumacher | 1 | 1 |
| Robert Nichols | 1 | 1 |
| Joseph Cremonese | 1 | 1 |
| Reinhard Vogt | 1 | 1 |
| James Segasture | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.